Cutting-edge compounds in the clinical pipeline and newest research, before they hit the market.
Tetrahydropyridinylpyrrolopyridine 5-HT2A partial agonists;
Navitoclax; RG 7423; RG 7433; CAS 923564-51-6
Goralatide; Seraspenide; Thymosin Beta-4 Fragment (1-4); TB4
ANAVEX 3-71; ANAVEX®3-71
GSBR-1290
NN 9487
AF710B; ANAVEX 3-71
SRK-015; apitegromab (WHO INN)
4C-D; 4C-DOM; BL-3912A; 2-amino-1-(2,5-dimethoxy-4-methylphe
ART27.13; Artelo-27.13; AstraZeneca-derived cannabinoid agon
O-304; OS-01; CAS 1261289-04-6
RG1662, RO5186582, NTX-1511
BYM338; LY3985863; anti-ACVR2B antibody
Salvin; diAcCA (semi-synthetic pro-drug derivative); CAS 365
CB-03-01; Cortexolone 17α-propionate; Breezula (investigatio
Ampakine CX717; RespireRx CX717
DLX159; Delix Therapeutics pipeline candidate (third-in-clas
EB-003 (Enveric Biosciences development code); "neurostabilo
LY3841136
GYM-329; RG6237; RG-70240
GTx-024, MK-2866, Ostarine, S-22
RS-5441
FST-315, FS-315, human follistatin serum isoform, follistati
REGN2477; garetosmab (INN)
Bis-(N-monosuccinyl-L-seryl-L-methionine) hexamethylenediami
GT-20029; AR-PROTAC; androgen receptor PROTAC (topical)
S14G-Humanin, Gly14-Humanin, (Gly14)-Humanin, HNG peptide
IBIO-600; anti-myostatin/GDF-11 monoclonal antibody (AstralB
(+)-JRT; isotryptamine-LSD; Tuck compound (informal)
JW0061; first-in-class GFRA1 agonist (JW Pharmaceutical inte
ActRII-Fc fusion; Keros Therapeutics development code KER-06
KP1, KL1-derived peptide, Klotho-derived peptide 56-87, Klot
A3051; KY-19382; CAS 2226664-93-1
AT-1001; CedLara (Phase 3 trial designation)
AMG 133; MariTide (development brand name)
INV-202, MRI-1891, S-MRI-1891
NYX-2925; (2S,3R)-3-hydroxy-2-((R)-5-isobutyryl-1-oxo-2,5-di
TAK-861
ZP8396
Psilera-002; proprietary internal designation (no public dev
KX-826; KX-826 tincture 1.0%
Luvesilocin; 4-OH-DiPT prodrug; 5-((3-(2-(diisopropylamino)e
Small Humanin-Like Peptide 2; SHLP-2; MT-RNR2-derived peptid
SRK-439; Scholar Rock anti-myostatin antibody
BHV-2000; BMS-986089; RG6206; RO7239361
PF-06649751; CVL-751
GEKG peptide; TEGO Pep 4-17; TEGO Pep 4-17 MB; H-Gly-Glu-Lys
NA-831; cyclic glycine-proline (cGP); cycloprolylglycine (CP
REGN1033; SAR391786
UBT-251; GLP-1/GIP/glucagon triple agonist (United Bio-Techn
Visudyne; benzoporphyrin derivative monoacid ring A (BPD-MA)
AQW-051; CAS 669770-29-0; development code AQW051
DLX-001; AAZ-A-154
CT1812; CT-1812
No compounds match that risk filter.
Medical & legal disclaimer. This site is for informational and harm-reduction purposes only. It is not medical advice and is not a substitute for a licensed healthcare professional. The compounds discussed are largely not approved by the FDA for human use and many are sold strictly as research chemicals 'not for human consumption.' Nothing here is an endorsement to purchase, possess, or use any substance. Laws vary by jurisdiction. Always consult a qualified physician and follow the law where you live.
Some links on this page may be affiliate links. If you buy through them we may earn a commission at no extra cost to you. This never changes the safety information we publish.